netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Tocilizumab found 14 matches

Open monograph to display formulary status BNF Category
  Tocilizumab  (RoActemra®) Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Restricted Drug Remdesivir  (Veklury®) Infections - COVID-19 therapeutics - 05.03.06
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (July 2019): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation (10.01.03)
link in drug section NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in subsection NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA518: Tocilizumab for treating giant cell arteritis (10.01.03)
link in drug section NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03.06)
link in drug section NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03.06)
link in drug section NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (05.03.06)
link in drug section North of Tyne, Gateshead and North Cumbria - Tocilizumab monitoring Shared Care Guideline 2023 (10.01.03)


 

netFormulary